These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 16707410)
1. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. Damholt B; Golor G; Wierich W; Pedersen P; Ekblom M; Zdravkovic M J Clin Pharmacol; 2006 Jun; 46(6):635-41. PubMed ID: 16707410 [TBL] [Abstract][Full Text] [Related]
2. The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen. Kapitza C; Zdravkovic M; Hindsberger C; Flint A Adv Ther; 2011 Aug; 28(8):650-60. PubMed ID: 21792552 [TBL] [Abstract][Full Text] [Related]
3. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. Kapitza C; Zdravkovic M; Zijlstra E; Segel S; Heise T; Flint A J Clin Pharmacol; 2011 Jun; 51(6):951-5. PubMed ID: 20671294 [No Abstract] [Full Text] [Related]
4. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Montanya E; Sesti G Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994 [TBL] [Abstract][Full Text] [Related]
5. Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Morrow L; Hompesch M; Guthrie H; Chang D; Chatterjee DJ Diabetes Obes Metab; 2011 Jan; 13(1):75-80. PubMed ID: 21114606 [TBL] [Abstract][Full Text] [Related]
6. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Bode B Diabetes Res Clin Pract; 2012 Jul; 97(1):27-42. PubMed ID: 22245694 [TBL] [Abstract][Full Text] [Related]
7. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Flint A; Kapitza C; Hindsberger C; Zdravkovic M Adv Ther; 2011 Mar; 28(3):213-26. PubMed ID: 21340616 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. Watson E; Jonker DM; Jacobsen LV; Ingwersen SH J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507 [TBL] [Abstract][Full Text] [Related]
9. Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug. Jacobsen LV; Vouis J; Hindsberger C; Zdravkovic M J Clin Pharmacol; 2011 Dec; 51(12):1696-703. PubMed ID: 21228406 [TBL] [Abstract][Full Text] [Related]
10. Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Malm-Erjefält M; Bjørnsdottir I; Vanggaard J; Helleberg H; Larsen U; Oosterhuis B; van Lier JJ; Zdravkovic M; Olsen AK Drug Metab Dispos; 2010 Nov; 38(11):1944-53. PubMed ID: 20709939 [TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics, pharmacodynamics, and tolerability of liraglutide, a once-daily human GLP-1 analogue, after multiple subcutaneous administration in healthy Chinese male subjects. Jiang J; Zhang J; Jacobsen LV; Hu P J Clin Pharmacol; 2011 Dec; 51(12):1620-7. PubMed ID: 21273395 [TBL] [Abstract][Full Text] [Related]
12. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Nauck MA; Hompesch M; Filipczak R; Le TD; Zdravkovic M; Gumprecht J; Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):417-23. PubMed ID: 17039422 [TBL] [Abstract][Full Text] [Related]
13. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes. Horowitz M; Flint A; Jones KL; Hindsberger C; Rasmussen MF; Kapitza C; Doran S; Jax T; Zdravkovic M; Chapman IM Diabetes Res Clin Pract; 2012 Aug; 97(2):258-66. PubMed ID: 22446097 [TBL] [Abstract][Full Text] [Related]
14. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes. Ryan GJ; Hardy Y J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609 [TBL] [Abstract][Full Text] [Related]
15. Next-generation GLP-1 therapy: an introduction to liraglutide. Repas T Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107 [TBL] [Abstract][Full Text] [Related]
16. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Davies MJ; Kela R; Khunti K Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109 [TBL] [Abstract][Full Text] [Related]
17. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide]. Reboldi G G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Elbrønd B; Jakobsen G; Larsen S; Agersø H; Jensen LB; Rolan P; Sturis J; Hatorp V; Zdravkovic M Diabetes Care; 2002 Aug; 25(8):1398-404. PubMed ID: 12145241 [TBL] [Abstract][Full Text] [Related]
19. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Pi-Sunyer X; Astrup A; Fujioka K; Greenway F; Halpern A; Krempf M; Lau DC; le Roux CW; Violante Ortiz R; Jensen CB; Wilding JP; N Engl J Med; 2015 Jul; 373(1):11-22. PubMed ID: 26132939 [TBL] [Abstract][Full Text] [Related]
20. Attempted suicide with liraglutide overdose did not induce hypoglycemia. Nakanishi R; Hirose T; Tamura Y; Fujitani Y; Watada H Diabetes Res Clin Pract; 2013 Jan; 99(1):e3-4. PubMed ID: 23149376 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]